The effect of alogliptin and pioglitazone combination therapy on various aspects of β-cell function in patients with recent-onset type 2 diabetes

European Journal of Endocrinology

Volumn 170, Issue 4, 2014, Pages 565-574

  Van Raalte, Daniël H ^a   Van Genugten, Renate E ^a   Eliasson, Björn ^b   Möller Goede, Diane L ^a   Mari, Andrea ^c   Tura, Andrea ^c   Wilson, Craig ^d   Fleck, Penny ^d   Taskinen, Marja R ^e   Smith, Ulf ^b   Diamant, Michaela ^a  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

^b Lundberg Laboratory for Cancer Research   (Sweden)

^c CNR   (Italy)

^d Takeda Global Research and Development Centre (Europe) Ltd   (United Kingdom)

^e UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ALOGLIPTIN; GLUCOSE; HEMOGLOBIN A1C; METFORMIN; PIOGLITAZONE; PLACEBO; SULFONYLUREA;

ADULT; AGED; ARTICLE; CELL FUNCTION; CONSTIPATION; CONTROLLED STUDY; DIABETES CONTROL; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NEPHROLITHIASIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PANCREAS ISLET BETA CELL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; STOMACH ULCER;

AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN-SECRETING CELLS; MALE; MIDDLE AGED; PIPERIDINES; THIAZOLIDINEDIONES; TREATMENT OUTCOME; URACIL;

EID: 84899487884     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-13-0639     Document Type: Article

References (36)

1. Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009 58 773-795. (doi:10.2337/db09-9028)
2. Weyer C, Bogardus C, Mott DM & Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. Journal of Clinical Investigation 1999 104 787-794. (doi:10.1172/JCI7231)
3. Saydah SH, Fradkin J & Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. Journal of the American Medical Association 2004 291 335-342. (doi:10.1001/jama.291.3.335)
4. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R & Matthews DR. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012 55 1577-1596. (doi:10.1007/s00125-012- 2534-0)
5. Zinman B. Initial combination therapy for type 2 diabetes mellitus: is it ready for prime time? American Journal of Medicine 2011 124 S19-S34. (doi:10.1016/j.amjmed.2010.11.003)
6. Esposito K, Bellastella G & Giugliano D. When metformin fails in type 2 diabetes mellitus. Archives of Internal Medicine 2011 171 365-366. (doi:10.1001/archinternmed.2011.4)
7. Zinman B, Harris SB, Neuman J, Gerstein HC, Retnakaran RR, Raboud J, Qi Y & Hanley AJ. Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study. Lancet 2010 376 103-111. (doi:10.1016/S0140-6736 (10) 60746-5)
8. Van Genugten RE, Van Raalte DH & Diamant M. Dipeptidyl peptidase-4 inhibitors and preservation of pancreatic islet-cell function: a critical appraisal of the evidence. Diabetes, Obesity and Metabolism 2012 14 101-111. (doi:10.1111/j.1463-1326.2011.01473.x)
9. Van Genugten RE, Van Raalte DH & Diamant M. Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide. Diabetes Research and Clinical Practice 2009 86 (Suppl 1) S26-S34. (doi:10.1016/S0168-8227 (09) 70006-3)
10. Van Genugten RE, Moller-Goede DL, Van Raalte DH & Diamant M. Extra-pancreatic effects of incretin-based therapies: potential benefit for cardiovascular-risk management in type 2 diabetes. Diabetes, Obesity & Metabolism 2013 15 593-606. (doi:10.1111/dom.12050)
11. Campbell IW & Mariz S. β-cell preservation with thiazolidinediones. Diabetes Research and Clinical Practice 2007 76 163-176. (doi:10.1016/j.diabres.2006.08.015)
12. Garber AJ, Schweizer A, Baron MA, Rochotte E & Dejager S. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes, Obesity and Metabolism 2007 9 166-174. (doi:10.1111/j.1463-1326.2006.00684.x)
13. Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P & Sitagliptin Study G. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clinical Therapeutics 2006 28 1556-1568. (doi:10.1016/j.clinthera.2006.10.007)
14. De Fronzo RA, Burant CF, Fleck P, Wilson C, Mekki Q & Pratley RE. Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes. Journal of Clinical Endocrinology and Metabolism 2012 97 1615-1622. (doi:10.1210/jc.2011- 2243)
15. Rosenstock J, Kim SW, Baron MA, Camisasca RP, Cressier F, Couturier A & Dejager S. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes, Obesity and Metabolism 2007 9 175-185. (doi:10.1111/j.1463-1326.2006.00698.x)
16. Triplitt C, Cersosimo E & De Fronzo RA. Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment. Vascular Health and Risk Management 2010 6 671-690.
17. Eliasson B, Moller-Goede D, Eeg-Olofsson K, Wilson C, Cederholm J, Fleck P, Diamant M, Taskinen MR & Smith U. Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study. Diabetologia 2012 55 915-925. (doi:10.1007/s00125-011-2447-3)
18. Levy JC, Matthews DR & Hermans MP. Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care 1998 21 2191-2192. (doi:10.2337/diacare.21.12.2191)
19. Mari A, Pacini G, Murphy E, Ludvik B & Nolan JJ. A model-based method for assessing insulin sensitivity from the oral glucose tolerance test. Diabetes Care 2001 24 539-548. (doi:10.2337/diacare.24.3.539)
20. Mari A, Schmitz O, Gastaldelli A, Oestergaard T, Nyholm B & Ferrannini E. Meal and oral glucose tests for assessment of β-cell function: modeling analysis in normal subjects. American Journal of Physiology. Endocrinology and Metabolism 2002 283 E1159-E1166.
21. Mari A, Tura A, Gastaldelli A & Ferrannini E. Assessing insulin secretion by modeling in multiple-meal tests: role of potentiation. Diabetes 2002 51 (Suppl 1) S221-S226. (doi:10.2337/diabetes.51.2007. S221)
22. Mari A & Ferrannini E. β-cell function assessment from modelling of oral tests: an effective approach. Diabetes, Obesity and Metabolism 2008 10 (Suppl 4) 77-87. (doi:10.1111/j.1463-1326.2008.00946.x)
23. Foley JE, Bunck MC, Moller-Goede DL, Poelma M, Nijpels G, Eekhoff EM, Schweizer A, Heine RJ & Diamant M. β cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naive patients with type 2 diabetes and mild hyperglycaemia: a randomised controlled trial. Diabetologia 2011 54 1985-1991. (doi:10.1007/s00125-011-2167-8)
24. Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, Mari A & De Fronzo RA. Thiazolidinediones improve β-cell function in type 2 diabetic patients American Journal of Physiology. Endocrinology and Metabolism 2007 292 E871-E883. (doi:10.1152/ajpendo.00551.2006)
25. Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, Ochoa C, Kawakubo M & Buchanan TA. Effect of pioglitazone on pancreatic β-cell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes 2006 55 517-522. (doi:10.2337/diabetes.55.02.06. db05-1066)
26. Vandewalle B, Moerman E, Lefebvre B, Defrance F, Gmyr V, Lukowiak B, Kerr Conte J & Pattou F. PPARγ-dependent and -independent effects of rosiglitazone on lipotoxic human pancreatic islets. Biochemical and Biophysical Research Communications 2008 366 1096-1101. (doi:10.1016/j.bbrc.2007.12.088)
27. Shah P, Vella A, Basu A, Basu R, Schwenk WF & Rizza RA. Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism 2000 85 4053-4059.
28. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B & Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993 36 741-744. (doi:10.1007/BF00401145)
29. Kintscher U & Law RE. PPARγ-mediated insulin sensitization: the importance of fat versus muscle. American Journal of Physiology. Endocrinology and Metabolism 2005 288 E287-E291. (doi:10.1152/ajpendo.00440.2004)
30. Weissman P, Goldstein BJ, Rosenstock J, Waterhouse B, Cobitz AR, Wooddell MJ & Strow LJ. Effects of rosiglitazone added to submaximal doses of metformin compared with dose escalation of metformin in type 2 diabetes: the EMPIRE Study. Current Medical Research and Opinion 2005 21 2029-2035. (doi:10.1185/030079905X74844)
31. Lewis JD, Ferrara A, Peng T, Hedderson M, Bilker WB, Quesenberry CP Jr, Vaughn DJ, Nessel L, Selby J & Strom BL. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care 2011 34 916-922. (doi:10.2337/dc10-1068)
32. Kahn SE, Zinman B, Lachin JM, Haffner SM, Herman WH, Holman RR, Kravitz BG, Yu D, Heise MA, Aftring RP et al. Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 2008 31 845-851. (doi:10.2337/dc07-2270)
33. Kahn SE, Lachin JM, Zinman B, Haffner SM, Aftring RP, Paul G, Kravitz BG, Herman WH, Viberti G, Holman RR et al. Effects of rosiglitazone, glyburide, and metformin on β-cell function and insulin sensitivity in ADOPT. Diabetes 2011 60 1552-1560. (doi:10.2337/db10-1392)
34. Consoli A & Formoso G. Do thiazolidinediones still have a role in treatment of type 2 diabetes mellitus? Diabetes, Obesity and Metabolism 2013 15 967-77. (doi:10.1111/dom.12101)
35. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefebvre PJ, Murray GD et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005 366 1279-1289. (doi:10.1016/S0140-6736 (05) 67528-9)
36. Rijkelijkhuizen JM, Girman CJ, Mari A, Alssema M, Rhodes T, Nijpels G, Kostense PJ, Stein PP, Eekhoff EM, Heine RJ et al. Classical and modelbased estimates of β-cell function during a mixed meal vs an OGTT in a population-based cohort. Diabetes Research and Clinical Practice 2009 83 280-288. (doi:10.1016/j.diabres.2008.11.017)